Julien Volet

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Conroy, Pascal Hammel, Mohamed Hebbar et al. · New England Journal of Medicine · 2018 · 2.7K citations · Full text

Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.

Thierry Conroy, Pascal Hammel, Mohamed Hebbar et al. · Journal of Clinical Oncology · 2018 · 138 citations

Surgical Oncology, Lba4001 Background, Gastroenterology +17

FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).

Laëtitia Dahan, Jean–Marc Phelip, Karine Le Malicot et al. · Journal of Clinical Oncology · 2018 · 53 citations

Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis

Capucine Baldini, Anne Escande, Olivier Bouché et al. · Pancreatology · 2016 · 39 citations

Surgical Oncology, Pancreatic Cancer, Elderly Patients +11

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

Thomas Aparicio, Michel Ducreux, Roger Faroux et al. · European Journal of Cancer · 2018 · 39 citations · Full text

Obesity, Ffcd Trials, Gastrointestinal Oncology +9